onr:"swepub:oai:DiVA.org:liu-136169"
Search: onr:"swepub:oai:DiVA.org:liu-136169" > Chemotherapy vs tam...
- 1 of 1
- Previous record
- Next record
- To hitlist
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
-
- Lindemann, Kristina (author)
- Oslo University Hospital, Norway; University of Sydney, Australia; Westmead Hospital, Australia
-
- Gibbs, Emma (author)
- University of Sydney, Australia
-
- Åvall-Lundqvist, Elisabeth, 1957- (author)
- Karolinska Institutet,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Institute, Sweden
- show more...
- show less...
- (creator_code:org_t)
- 2017-01-24
- 2017
- English.
- In: British Journal of Cancer. - : NATURE PUBLISHING GROUP. - 0007-0920 .- 1532-1827. ; 116:4, s. 455-463
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. Methods: Patients with PROC were randomised (2 : 1) to chemotherapy (weekly paclitaxel 80 mg m(-2) or four weekly pegylated liposomal doxorubicin 40 mg m(-2)) or tamoxifen 40mg daily. The primary end point was HRQoL. Secondary end points were PFS by RECIST and overall survival (OS). Results: Between March 2002 and December 2007, 156 and 82 patients were randomised to chemotherapy and tamoxifen, respectively. In the chemotherapy arm, a significantly larger proportion of patients experienced a worsening in their social functioning. There was no difference in the proportion of patients experiencing improvement of gastrointestinal symptoms. Median PFS on tamoxifen was 8.3 weeks (95% CI, 8.0-10.4) compared with 12.7 weeks (95% CI, 9.0-16.3) on chemotherapy (HR, 1.54; 95% CI, 1.16-2.05; log-rank P = 0.003). There was no difference in OS between the treatment arms. Conclusions: Patients on chemotherapy had longer PFS but experienced more toxicity and poorer HRQoL compared with tamoxifen. Control over gastrointestinal symptoms was not better on chemotherapy. These data are important for patient counselling and highlight the need to incorporate HRQoL end points in studies of PROC.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Keyword
- platinum-resistent ovarian cancer; chemotherapy; tamoxifen; quality of life; survival; phase III
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- British Journal of Cancer (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Lindemann, Krist ...
- Gibbs, Emma
- Åvall-Lundqvist, ...
- dePont Christens ...
- Woie, Kathrine
- Kalling, Marten
- show more...
- Auranen, Annika
- Grenman, Seija
- Hoegberg, Thomas
- Rosenberg, Per
- Skeie-Jensen, To ...
- Hjerpe, Elisabet
- Dorum, Anne
- Gebski, Val
- Kristensen, Gunn ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Surgery
- Articles in the publication
- British Journal ...
- By the university
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
